𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase 2 trial of sorafenib in patients with advanced urothelial cancer : A Trial of the Eastern Cooperative Oncology Group

✍ Scribed by Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J. Roth; George Wilding

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
132 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Overview of advanced urothelial cancer t
Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group
✍ Robert Dreicer; Bruce Roth; George Wilding πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

Advanced transitional cell carcinoma of the urothelium is an aggressive malignancy characterized by a median survival period of less than 1 year. Although this disease is moderately chemotherapy-sensitive, to the authors' knowledge the impact of therapy reported to date on survival has been minimal.

Phase 2 trial of pemetrexed disodium and
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) : A trial of the Eastern Cooperative Oncology Group
✍ Robert Dreicer; Hailun Li; Matthew M. Cooney; George Wilding; Bruce J. Roth πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. There is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelia

An eastern cooperative oncology group ph
An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma
✍ Robert S. Witte; Paul Elson; Janardan Khandakar; Donald L. Trump πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 359 KB πŸ‘ 2 views

## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.

Phase II trial of gemcitabine in patient
Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group
✍ Scott Okuno; Louise M. Ryan; John H. Edmonson; Dennis A. Priebat; Ronald H. Blum πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. ## METHODS Twenty‐five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Coo

Phase II trial of gemcitabine and doceta
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group
✍ Robert Dreicer; Judith Manola; Daniel J. Schneider; John F. Schwerkoske; Christo πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemothera